Volume | 681,891 |
|
|||||
News | - | ||||||
Day High | 8.81 | Low High |
|||||
Day Low | 7.91 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Actinium Pharmaceuticals Inc | ATNM | AMEX | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
7.95 | 7.91 | 8.81 | 8.75 | 7.78 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,578 | 681,891 | $ 8.44 | $ 5,752,144 | - | 4.00 - 9.8599 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:49:54 | 60 | $ 8.8543 | USD |
Actinium Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
239.32M | 27.41M | - | 81k | -48.82M | -1.78 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Actinium Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATNM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.96 | 8.81 | 6.47 | 7.22 | 251,481 | 1.79 | 25.72% |
1 Month | 8.99 | 9.68 | 6.47 | 8.08 | 303,461 | -0.24 | -2.67% |
3 Months | 5.12 | 9.8599 | 5.0927 | 8.08 | 374,214 | 3.63 | 70.90% |
6 Months | 5.49 | 9.8599 | 4.00 | 6.90 | 284,404 | 3.26 | 59.38% |
1 Year | 9.18 | 9.8599 | 4.00 | 7.00 | 235,728 | -0.43 | -4.68% |
3 Years | 7.66 | 15.12 | 4.00 | 8.07 | 298,298 | 1.09 | 14.23% |
5 Years | 0.30 | 15.12 | 0.1506 | 1.41 | 1,828,396 | 8.45 | 2,816.67% |
Actinium Pharmaceuticals Description
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia. |